The Type of Surgical Axillary Staging Following Neoadjuvant Systemic Treatment Has No Impact on Breast Cancer Patients’ Oncological Outcomes SLNB; safe staging post-NA setting
Abstract
Background: Although response-adjusted surgery is a highly recommended strategy following neoadjuvant systemic treatment (NAST), consensus on axillary management in cN+/ycN0 breast cancer patients is still lacking. In this setting, clinical significance of the higher false negative rate of sentinel lymph node biopsy (SLNB) procedure is unknown. The present analysis aims to evaluate the long-term safety of the SLNB in ycN0 patients.
Methods: In this study, 60 patients with the operable breast cancer, undergoing surgery after NAST in Clinical Hospital Centre Rijeka, Croatia, from May 2016 to May 2018, were included in the analysis. Following a preliminary retrospective analysis in 2019, follow-up (FU) was extended, and all outcomes were re-evaluated in December 2022.
Results: The median FU time was 65 months and 98% of patients had complete FU data. In the ypN0 group, ALND was performed for 15 and SLNB for 20 patients. The median number of LN retrieved in ALND and SLNB was 15 and 3, respectively. The method of surgical axillary staging had no impact on oncological outcomes; Regional Recurrence Free Survival Chi-square=0.5789, P=0.4467; Distant Recurrence Free Survival Chi-square=1.3658, p=0.2425; Breast Cancer Specific Survival Chi-square=0.9755, P=0.3233.
Conclusion: Irrespective of a higher FNR following NAST, as compared to the upfront surgery setting, SLNB is a safe procedure and should be considered for all ycN0 patients, regardless of pre-treatment cN status.
Full text article
References
Fisher B, Montague E, Redmond C, Deutsch M, Brown GR, Zauber A et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer. 1980;46(1):1-13. doi: 10.1002/1097-0142(19800701)46:1<1::aid-cncr2820460102>3.0.co;2-3.
Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6 Suppl):2827-39. doi: 10.1002/1097-0142(197706)39:6<2827::aid-cncr2820390671>3.0.co;2-i.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-8; discussion 398-401. doi: 10.1097/00000658-199409000-00015.
Giuliano AE. Mapping a pathway for axillary staging: a personal perspective on the current status of sentinel lymph node dissection for breast cancer. Arch Surg. 1999;134(2):195-9. doi: 10.1001/archsurg.134.2.195.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-53. doi: 10.1056/NEJMoa012782.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33. doi: 10.1016/S1470-2045(10)70207-2.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4.
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-75. doi: 10.1001/jama.2011.90.
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926. doi: 10.1001/jama.2017.11470.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7.
Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight-year follow-up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672-679. doi: 10.1016/j.ejso.2016.12.011.
Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care 2017;12(2):102-107. doi: 10.1159/000475698.
www.NCCN.org [Internet]. Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2023 — March 23, 2023 [approached 2023 Apr 5]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9.
Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258-64. doi: 10.1200/JCO.2014.55.7827.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61. doi: 10.1001/jama.2013.278932.
Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343-352. doi: 10.1007/s10549-018-5004-7.
Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-702. doi: 10.1200/JCO.2005.05.188.
Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539-46. doi: 10.1002/bjs.5209.
Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16(5):551-63. doi: 10.1016/j.acra.2009.01.026.
Tan VK, Goh BK, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis. J Surg Oncol. 2011;104(1):97-103. doi: 10.1002/jso.21911.
Geng C, Chen X, Pan X, Li J. The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(9):e0162605. doi: 10.1371/journal.pone.0162605.
Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361-8. doi: 10.1016/j.ejso.2015.11.019.
Nogi H, Uchida K, Mimoto R, Kamio M, Shioya H, Toriumi Y, et al. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. Clin Breast Cancer. 2017;17(8):644-649. doi: 10.1016/j.clbc.2017.05.002.
Car Peterko A, Avirović M, Mance D, Valković Zujić P, Belac Lovasić I, Lovasić F. Clinical impact of sentinel lymph node biopsy after neoadjuvant treatment in the breast cancer patients with initially involved axillary lymph nodes (single-center experience). Abstracts/Euro Jour Surg Oncol. 2020;46:e38-e39. doi:10.1016/j.ejso.2019.11.065.
Car Peterko A, Avirović M, Mance D, Valković Zujić P, Belac Lovasić I, Lovasić F. Clinical impact of sentinel lymph node biopsy after neoadjuvant treatment in breast cancer patients with initially involved axillary lymph nodes; single-center experience- preliminary analysis. Libri Oncol. 2020; 48(1);1-7 doi: 10.20471/LO.2020.48.01.01.
Gasparri ML, De Boniface J, Gentilini OD, Kaidar-Person O, Poortmans P, Kuehn T. Perspectives on axillary management after primary systemic treatment: An international EUBREAST survey [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-01-16. doi: 10.1158/1538-7445.SABCS21-P1-01-16.
Diepstraten SC, Sever AR, Buckens CF, Veldhuis WB, van Dalen T, van den Bosch MA, et al. Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21(1):51-9. doi: 10.1245/s10434-013-3229-6.
Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB, Smidt ML. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast. 2013;22(6):1108-13. doi: 10.1016/j.breast.2013.09.002.
Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19(1):667. doi: 10.1186/s13063-018-3021-9.
A Randomized Phase III Clinical Trial Evaluation Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. NSABP-51/RTOG 1304 Trial, NCT01872975, available from: https://clinicaltrials.gov/ct2/show/NCT01872975
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. Alliance A11202 Trial, NCT01872975, available from: https://clinicaltrials.gov/ct2/show/NCT01901094
Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, et al. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017;152(7):665-670. doi: 10.1001/jamasurg.2017.0562.
Shi Z, Wang X, Qiu P, Liu Y, Zhao T, Sun X et al. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy. Gland Surg. 2021 Jan;10(1):166-174. doi: 10.21037/gs-20-573.
Car Peterko A, Avirović M, Valković Zujić P, Belac Lovasić I, Lovasić F. Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in Luminal B, HER-2 positive and triple negative breast cancer patients with initially involved axillary lymph node(s). Protocol for prospective, non-randomised, observational clinical trial. Libri Oncol. 2019;47(1):29–34. doi: 10.20471/LO.2019.47.01.06.
Car Peterko A, Avirović M, Skočilić I, Valković Zujić P, Belac Lovasić I, Lovasić F. Overall survival and disease control rates for operable invasive breast cancer in the era of conservative surgery; retrospective, institutional, and five-year follow-up data. Libri Oncol. 2020;48(2-3);61-67 doi: 10.20471/LO.2020.48.02-03.11.
Authors
Copyright (c) 2023 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.